Patrick Van Dreden, PhD

Clinical Research Manager
Diagnostica Stago
Gennevilliers, Ile-de-France, France

Patrick Van Dreden Head of the Clinical Research Department (Diagnostica Stago) has established a clinical research program for the exploration of clinically relevant biomarkers of hypercoagulability in patients at risk of venous thromboembolism. He has contributed as an expert to the development of several guidelines, for the Prophylaxis and Treatments of VTE, Thrombophilia and Venous Thromboembolis and for the treatment and prophylaxis of thrombosis in cancer patients. He is also member several scientific association has published extensively in peer-reviewed international journals and has authored several book chapters.

Presentation(s):

• PB0048 - Procoagulant activity of phospholipids is correlated with thrombin generation parameters: preliminary results from an angiographically-controlled study

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 20.4 - Preoperative DOAC Levels are Associated with Postoperative Bleeding and Effects are Mediated by Thrombin Generation Parameters - [SONAR]: A Nested Case-Control Study and Causal Mediation Analysis

  Sunday, June 23, 2024
  15:30 – 15:45 ICT

• PB0598 - Primary role in assessing the risk of severe early onset preeclampsia of phospholipid-dependent procoagulant clotting time and initiation phase of thrombin generation test

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0600 - Tissue factor, leukemia inhibitory factor , thrombomodulin, D-Dimer, thrombin generation and procoagulant phospholipid dependent clotting time are predictive for in vitro fertilization outcome

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB1354 - Effect of tinzaparin, apixaban, enoxaparin and quercetin and on the expression of procoagulant properties of cancer cells and endothelial cells exposed to cancer cell derived microvesicles

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1403 - Impact of determining clinical risk factors and biomarkers on the risk of cancer-associated thrombosis in newly diagnosed patients with multiple myeloma. The observational Roadmap-CAT-MM

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1410 - Plasma tissue factor activity and D-dimer in lung cancer patients predicts venous thromboembolism and poor overall survival

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1360 - Plasmapheresis before lung transplantation is associated with an increase in tissue factor activity and procoagulant phospholipids

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1112 - The procoagulant signature of cancer cells drives fibrin network formation in tumor microenvironment and impacts its quality. Implications in cancer cell migration

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT